EPSILOGEN
LIVE

Serial Number

88885762

Owner

Epsilogen Ltd

Attorney

Susan Piascik Christoff

Filing Date

Apr 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

EPSILOGEN Trademark

Serial Number: 88885762 • Registration: 6505086

EPSILOGEN is a trademark filed by Epsilogen Ltd on April 24, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Epsilogen Ltd (2 trademarks)

2 Royal College Street
London NW10NH , GB

Entity Type: 99

Trademark Details

Filing Date

April 24, 2020

Registration Date

October 5, 2021

Published for Opposition

July 20, 2021

Goods & Services

Pharmaceutical drugs for suppressing tumors; pharmaceutical drugs for treating malignant tumors; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing agents; immunostimulants; medicine for suppressing tumors; medicine for treating malignant tumors; medicine for the treatment of cancer; diagnostic reagents for medical laboratory use

Medical treatment services of cancerous diseases; medical screening of cancerous diseases; medical diagnostic monitoring, testing, and analysis services; medical services, namely, diagnosis and treatment of cancerous diseases; pharmaceutical services, namely, dispensing pharmaceuticals; pharmaceutical services, namely, pharmaceutical consultation; pharmaceutical services, namely, pharmaceutical compounding services; pharmaceutical advisory services; laboratory analysis services relating to the treatment of persons by medical laboratories; laboratory analysis services relating to the diagnosis and treatment of cancerous diseases by medical laboratories; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis by medical laboratories; medical services in the field of oncology, immunology and immuno-oncology; providing advice relating to oncology, immunology and immuno-oncology; providing on-line information relating to oncology, immunology and immuno-oncology

Scientific and technological services, namely, scientific research in the field of pharmaceutical research and development and research and design relating thereto; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; clinical research in the field of cancer treatment; clinical trials for others; conducting clinical trials for others in the field of pharmaceutical products; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; scientific research for medical purposes in the area of cancerous diseases; research and development services of technology in the fields of oncology, immunology and immuno-oncology

Filing History

REGISTERED-PRINCIPAL REGISTER
Oct 5, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 20, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 20, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 30, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 15, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2021 CRFA
ASSIGNED TO LIE
May 4, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 21, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 23, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jul 23, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jul 23, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2020 NWOS
NEW APPLICATION ENTERED
Apr 28, 2020 NWAP